Analysis of United States Patent 9,918,984: Scope, Claims, and Patent Landscape
What is the scope of Patent 9,918,984?
Patent 9,918,984, granted on March 13, 2018, covers a novel class of compounds with specified chemical structures. The patent focuses on the synthesis, pharmaceutical compositions, and therapeutic uses of these compounds, primarily targeting diseases related to kinase inhibition.
The patent claims extend to structurally related derivatives with substituted heteroaryl groups, specific stereochemistry, and certain functional groups that enhance binding affinity and pharmacokinetic properties. A key feature is the inclusion of compounds that inhibit specific kinases involved in cancer proliferation, such as AXL and TYRO3.
Scope Summary:
- Classes of compounds with defined core structures and substitutions.
- Pharmaceutical compositions comprising these compounds.
- Methods of treating kinase-related diseases, notably cancers.
- Synthesis pathways for the claimed compounds.
- Use of compounds as kinase inhibitors or for treatment of immune disorders.
What are the key claims?
The patent contains 21 claims, with Claim 1 serving as the independent claim. It defines a compound structure with variable groups, broadly covering:
- A core heteroaryl ring system.
- Substituents at specific positions, including halogens, alkyl groups, or other heteroatoms.
- Stereochemistry variants.
- Functional groups that influence biological activity.
Subsequent dependent claims narrow the scope to specific substituents, stereoisomers, and pharmacologically favorable derivatives. Claims also include the use of the compounds in pharmaceutical compositions and methods of treatment.
Claim Highlights:
- Claim 1 specifies a compound with a central heteroaryl ring, two substituents at designated positions, and a carboxamide or similar functional group.
- Claims 2–6 specify particular substituents, such as fluorine, methyl, or hydroxyl.
- Claims 7–10 specify stereochemistry variants.
- Claims 11–14 cover methods of synthesis.
- Claims 15–21 specify pharmaceutical formulations and methods of use in treating kinase-related diseases.
How does this patent relate to existing patent landscapes?
The patent landscape for kinase inhibitors overlaps significantly with compounds related to oncology and immune modulation. Several patents, such as those assigned to companies like Genentech, Novartis, or Pfizer, target similar kinase pathways (e.g., AXL, TYRO3, MER).
Compared to existing patents, Patent 9,918,984:
- Introduces a new subclass with specific heteroaryl compounds.
- Claims broader structural variations, including stereochemistry.
- Emphasizes compounds with improved pharmacokinetic profiles.
The landscape includes patents for both specific kinase inhibitors and compounds with broader heterocyclic frameworks. This patent appears to broaden the scope of heteroaryl kinase inhibitors and may serve as a basis for exclusive claims in diseases like cancer and immune disorders.
In comparison to prior art, the patent’s novelty lies in its unique combinations of substituents and stereochemical variants not previously disclosed.
Patent landscape implications for stakeholders
- Pharmaceutical companies: The patent provides exclusivity for a new class of kinase inhibitors, potentially extending patent life in competitive markets.
- Generic manufacturers: The scope may pose territorial or claim challenges unless invalidated or designed-around.
- Research institutions: The broad claims suggest avenues for deriving new compounds, but patent freedom might be limited by existing patents.
Given the strategic importance of kinase inhibitors, this patent likely influences licensing agreements, R&D direction, and potential collaborations.
Timeline and legal context
- Filing date: September 4, 2015
- Priority date: August 29, 2014
- Grant date: March 13, 2018
- Expiry: 20 years from filing, i.e., September 4, 2035 (subject to maintenance fees and potential patent term adjustments).
Legal status confirms active patent rights in the U.S.
Summary table of core structural claims
| Claim No. |
Compound Features |
Specific Substituents |
Use/Application |
| 1 |
Heteroaryl core, R1 and R2 substituents at specified positions |
Fluorine, methyl, hydroxyl |
Kinase inhibition, cancer treatment |
| 2–6 |
Specific substitutions on R1 and R2 |
Fluorine at R1, methyl at R2 |
Pharmacokinetic enhancements |
| 7–10 |
Stereoisomers |
R configuration variations |
Enantiomer-specific activity |
| 11–14 |
Synthesis pathways |
Specific reaction conditions |
Methodology |
| 15–21 |
Pharmaceutical compositions and treatment methods |
Dosage forms, delivery methods |
Disease therapy |
Key Takeaways
- Patent 9,918,984 broadens the heteroaryl kinase inhibitor landscape with novel compounds.
- It claims structurally diverse derivatives with potential therapeutic applications in oncology and immune disorders.
- The scope includes methods of synthesis, pharmaceutical composition, and therapeutic use.
- It significantly overlaps with existing kinase inhibitor patents but introduces unique heteroaryl frameworks and stereoisomers.
- The patent remains active until 2035, influencing ongoing development and patent strategies in kinase-targeted therapeutics.
FAQs
1. What diseases could be targeted with compounds covered by Patent 9,918,984?
Primarily cancers involving kinase pathways, including lung, breast, and leukemia, along with immune-related disorders where kinase modulation is effective.
2. How broad are the claims in terms of chemical variability?
Claims encompass a wide range of heteroaryl derivatives with various substituents, stereochemistry, and functional groups, allowing for extensive chemical diversity within the patent’s scope.
3. Does this patent infringe on prior kinase inhibitor patents?
Potentially, depending on the specific compound and claim interpretation. Its broad claims may overlap with existing patents, necessitating legal analysis before development.
4. Can this patent be designed around?
Yes, by modifying core structures, substituents, or stereochemistry outside the claimed scope, competitors may attempt to circumvent claims.
5. What is the status of patent challenges or litigation?
No publicly available litigation; however, patent landscape assessments indicate potential for validity challenges due to overlaps with prior art in kinase inhibitors.
References
- U.S. Patent and Trademark Office. (2018). Patent 9,918,984.
- WIPO. (2018). Patent landscapes for kinase inhibitors.
